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Background. Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients
with severe influenza.
Methods. Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal impairment,
for up to 10 days. Primary outcomes included adverse events (AEs), and clinical/laboratory parameters. Pharmaco-
kinetics, viral load, and disease course were also assessed.
Results. One hundred thirty patients received intravenous zanamivir (median, 5 days; range, 1–11) a median of
4.5 days (range, 1–7) after onset of influenza; 83% required intensive care. The most common influenza type/
subtype was A/H1N1pdm09 (71%). AEs and serious AEs were reported in 85% and 34% of patients, respectively;
serious AEs included bacterial pulmonary infections (8%), respiratory failure (7%), sepsis or septic shock (5%), and
cardiogenic shock (5%). No drug-related trends in safety parameters were identified. Protocol-defined liver events
were observed in 13% of patients. The 14- and 28-day all-cause mortality rates were 13% and 17%. No fatalities were
considered zanamivir related. Pharmacokinetic data showed dose adjustments for renal impairment yielded similar
zanamivir exposures. Ninety-three patients, positive at baseline for influenza by quantitative polymerase chain reac-
tion, showed a median decrease in viral load of 1.42 log10 copies/mL after 2 days of treatment.
Conclusions. Safety, pharmacokinetic and clinical outcome data support further investigation of intravenous
zanamivir.
Clinical Trials Registration. NCT01014988.
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Pandemic influenza and seasonal influenza epidemics
are significant public health threats [1] that cause
substantial worldwide morbidity and mortality [2]. The
neuraminidase inhibitors oseltamivir and zanamivir
are the only widely used antivirals active against cur-
rently circulating influenza A and B viruses. Peramivir,
laninamivir, and other nonneuraminidase inhibitors are
available in some countries. Neuraminidase inhibitors act
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by inhibiting viral cleavage of sialic acid residues from surface gly-
coconjugates of infected cells, preventing virus release and spread
in the respiratory tract [3]. Oseltamivir (capsule and suspension)
and zanamivir (oral inhalation powder) are approved for treat-
ment and prophylaxis of acute uncomplicated influenza [4, 5].
However, no antiviral treatments have been proved to be effective
for complicated or severe influenza in controlled trials, and no
parenteral influenza antiviral formulations are licensed outside
China, Japan, and Korea.
Enzyme kinetics and crystallography studies show that zana-
mivir binding to the neuraminidase active site results in a low
propensity for resistance [6]. The H275Y neuraminidase muta-
tion is the most commonly reported influenza virus mutation,
conferring high-level resistance to oseltamivir among N1-con-
taining viruses, but retaining full susceptibility to zanamivir
[7]. In 2008, this mutation emerged in the seasonal H1N1
strain and spread in less than a year. Subsequently, oseltamivir
resistance was estimated at 1% during the 2009 A/H1N1 pan-
demic, 2.1% in the United States during the 2011–2012 season
[8], and 15% in a community outbreak in Australia [9].
Treatment options for influenza remain limited, and further
development of resistance continues to be a serious public health
threat. The 2009 pandemic disproportionately affected children,
younger adults, and pregnant women, and resulted in high rates
of acute respiratory distress syndrome, multiorgan failure, and
death among hospitalized populations. A medical need exists for
clinically proven safe and efficacious treatments with diverse re-
sistance profiles for severe influenza. Reliable systemic intrave-
nous administration may best suit hospitalized patients [10, 11].
Here we report findings from the adult cohort of a study
evaluating the safety and tolerability of an investigational intra-
venous formulation of zanamivir in hospitalized patients with
influenza. Assessments of pharmacokinetics, viral load, and
course of illness were also performed. The study is ongoing in
adolescent and pediatric patients.
METHODS
Study Design
This open-label, multicenter, single-arm, phase II study (Clini-
cal Trials registration NCT01014988; GSK NAI113678) was
conducted in 8 countries (Australia, Canada, France, Russia,
Spain, Thailand, United Kingdom, and United States). The
study was performed in accordance with ICH GCP and the
principles of the Declaration of Helsinki, and approved by local
ethics committees. Informed consent was obtained from the
patient or legal guardian before the study. Enrollment criteria
included age ≥18 years, hospitalization with severe or progres-
sive laboratory-confirmed influenza [12, 13] while receiving ap-
proved influenza antiviral medications or not being suitable for
treatment with approved antivirals (eg, unable to receive oral or
inhaled medication), and ability to receive the first dose of
intravenous zanamivir within 7 days after onset of influenza
symptoms. Patients were excluded if they required concurrent
therapy with another influenza antiviral medication or had ele-
vated alanine aminotransferase (ALT) ≥3 times the upper limit
of normal (ULN) and total bilirubin ≥2 × ULN, ALT
>5 × ULN, or unstable cardiac disease or arrhythmia at baseline
(detailed criteria available at www.clinicaltrials.gov).
Treatment
Intravenous zanamivir (600 mg) was administered over a 30-
minute period twice daily for 5 days, with the option to extend
treatment for up to 5 more days at the investigator’s discretion.
Intravenous zanamivir dosing was adjusted for patients with
renal impairment based on daily calculated creatinine clearance
(CLcr) or on estimated clearance while receiving continuous
renal replacement therapy (CLCRRT) [14, 15] after an initial
600-mg loading dose. The maintenance dose was 600 mg for
subjects with a CLcr/CLCRRT ≥80 mL/min, reduced as follows
for those with lower CLcr/CLCRRT values: 400 mg for 50 to
<80 mL/min, 250 mg for 30 to <50 mL/min, 150 mg for 15 to
<30 mL/min, and 60 mg for <15 mL/min. The interval between
the initial dose and the start of maintenance dosing was 24
hours for patients with a CLcr/CLCRRT of 15 to <30 mL/min
and 48 hours for those with a CLcr/CLCRRT of <15 mL/min.
For all other patients, maintenance doses were administered
every 12 hours (Supplementary Table 1). The dose rationale
was based on the prophylactic efficacy of intravenous zanamivir
[16] concentrations in lung epithelial lining fluid (range, 216–
1163 ng/mL) were many times greater than the median inhibi-
tory concentration for a range of influenza A and B neuramini-
dases after intravenous administration of zanamivir (600 mg);
these concentrations were 55%–79% of the corresponding
serum zanamivir concentrations [17].
Outcome Measures
Primary safety outcomes included adverse events (AEs) classified
according to the DAIDS toxicity scale [18], serious AEs (SAEs),
incidents of hepatic injury (liver AEs defined as ALT ≥5 × ULN;
liver SAEs defined as ALT ≥3 × ULN and total bilirubin
≥2 ×ULN; laboratory criteria of Hy’s law [19]), clinical laborato-
ry measurements, electrocardiographic data, and vital signs.
Secondary outcome measures included serum pharmacoki-
netic parameters and change in influenza viral load over time
(by quantitative real-time polymerase chain reaction [qRT-
PCR] and quantitative virus culture [qVC]; Quest Diagnostics).
Clinical end points included mortality rate, length of hospitaliza-
tion (as measured from study day 1), intensive care unit (ICU)
stay (total length of stay), and time until return to normal vital
signs, according to defined criteria. Exploratory outcomes in-
cluded influenza viral load quantification in samples obtained
from endotracheal aspirates and correlation analyses between
pharmacokinetic parameters, viral load, and clinical outcomes.
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Study Procedures
Safety and clinical outcomes were assessed daily during treat-
ment, then after treatment on days 2, 5, 9, 16, and 23 after the
last dose of intravenous zanamivir. Poststudy deaths attribut-
able to AEs that began during the study (or occurring during
the period of hospitalization) were also recorded, even if death
occurred after the end-of-study assessment.
Serum pharmacokinetic sampling was optional. Pharmaco-
kinetic samples for the initial dose were scheduled for collection
before and at 25–30 minutes (end of infusion) and 1–2, 4–6,
and 11–12 hours after the start of infusion. If the start of main-
tenance dosing was delayed for renal impairment, then addi-
tional samples were scheduled for 22–24 and 46–48 hours after
the dose. For the maintenance dose on day 3, 4 or 5, sample
collections were as for day 1, up to 12 hours after the dose.
Serum zanamivir concentrations were measured using a
validated assay based on protein precipitation, followed by
high-performance liquid chromatography–tandem mass spec-
trometry analysis. For a 50-µL aliquot of serum, the lower limit
of quantification (LLQ) was 10 ng/mL, and the upper limit
10 000 ng/mL. Pharmacokinetic parameters were estimated
from concentration-time data by standard noncompartmental
analysis using WinNonlin software, professional version 5.2
(Pharsight).
Nasopharyngeal swab samples (Copan Diagnostics) to assess
viral load and influenza subtype were collected on days 1–5 of
treatment. Additional samples were taken on days 7 and 10 if
dosing was continued beyond day 5, and on posttreatment as-
sessment days if patients continued to be hospitalized and
symptomatic. Optional endotracheal samples were collected at
a single time point between days 3 and 5. RNA was isolated
from nasopharyngeal and endotracheal samples, and 1-step
qRT-PCR was used to quantify levels of influenza RNA. The
LLQ for the assay was set at 2.7 log10 (500) copies/mL. Viral
titers were also deduced by median tissue culture infectious
dose (TCID50) calculation after serial dilution of samples, fol-
lowed by adsorption onto Madin-Darby canine kidney cells.
The number of plaque-forming units was used to calculate the
TCID50, with an LLQ of 0.4 log10 TCID50/mL.
Statistical Analysis
The planned sample size for the study was chosen to provide
enough patients to determine the safety and tolerability of
intravenous zanamivir in the patient population. With 130
enrolled patients, we can exclude AEs with a frequency >2.8%
with 95% confidence. Exploratory analyses of Cox regression
and Pearson correlation were performed to investigate associa-
tions between various outcomes, such as mortality, clinical and
virologic responses, hospital or ICU stay, clinical risk factors,
and pharmacokinetic parameters. Wilcoxon signed rank test




Between November 2009 and September 2011, 130 adult pa-
tients were enrolled from 30 centers. Three patients were preg-
nant (1 second trimester, 2 third trimester), and 1 patient was 1
day post partum. Patients were treated for a median of 5 days
(range, 1–11 days): 87 patients (67%) received intravenous za-
namivir for ≤5 days, and 43 (33%) received intravenous zana-
mivir for >5 days. Thirty patients (23%) were prematurely
withdrawn from intravenous zanamivir treatment, 12 (9%)
owing to (on-treatment) fatality, 11 (8%) at the discretion of
the investigator (most because of clinical improvement and
hospital discharge), 4 (3%) owing to AEs (cytolytic hepatitis,
hepatic enzyme elevation, renal failure, and rash), 2 (2%) owing
to withdrawal of consent, and 1 owing to protocol deviation.
Twenty-three patients (18%) did not complete the study; 20
(15%) owing to death, and 1 each owing to withdrawal of
consent, investigator discretion, or loss to follow-up.
Baseline patient characteristics and demographics are sum-
marized in Table 1. The most common influenza symptoms at
baseline were fever (82%), cough (81%), and dyspnea (72%);
77% of patients had ≥1 chronic underlying medical condition
(Table 1). Ten patients (8%) had documentation of influenza
Table 1. Baseline Characteristics, Demographics, and Chronic




Age, median (range), y 47.5 (18–94)
Male sex, No. (%) 74 (57)
Race, No. (%)
African American/African 10 (8)
East Asian/Southeast Asian 14 (11)
White/European 97 (75)
Other 9 (7)
Body mass index, median (range), kg/m2 25.5 (12–55)
Ventilation status at enrollment, No. (%)
Extracorporeal membrane oxygenation 3 (2)
Endotracheal mechanical ventilation 60 (46)
Renal replacement therapy at enrollment 6 (5)
Chronic underlying illnesses, summarized by organ
system, No. (%)
Any illness 100 (77)
Respiratory 42 (32)
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vaccination in the 9 months before presentation. Chest radio-
graphic evidence of pneumonia or pneumonitis was present at
the baseline in 112 of 126 patients (89%). The median time
from symptom onset to initiation of intravenous zanamivir was
4.5 days (range, 1–7 days), and 104 patients (80%) received
oseltamivir before study entry (median exposure, 2 days). The
most common influenza type/subtype was A/H1N1pdm09
(71%), followed by A/H3N2 (12%), influenza A subtype
unknown (11%), and influenza B (2%). Four percent of isolates
could not be typed.
Safety End Points
Overall AEs, SAEs, and grade 3 or 4 AEs were reported in 110
(85%), 44 (34%), and 57 (44%) patients, respectively. Summa-
ries of SAEs and grade 3/4 AEs are presented in Table 2 and
Table 3. A summary of all AEs is presented in Supplementary
Table 2.
In total, 28 patients (22%) reported AEs considered by the
investigator to have a possible causal relationship to zanamivir,
the most common were acute liver injury in 13 patients (10%),
rash in 4 (3%), and thrombophlebitis or venous thrombosis in
4 (3%). SAEs considered by the investigator to be possibly
zanamivir related included 2 cases of ventricular arrhythmia, 2
of acute liver injury meeting laboratory criteria of Hy’s law, 2 of
encephalopathy, and 1 of renal failure. One event of ventricular
arrhythmia (torsade de pointes) reported as possibly related to in-
travenous zanamivir occurred 16 days after completion of zana-
mivir treatment, and was confounded by haloperidol treatment.





All events 44 (34)
Bacterial pulmonary infections (including
pneumonia and bronchopneumonia)
10 (8)
Respiratory failure 9 (7)
Sepsis or septic shock 7 (5)
Cardiogenic shock 7 (5)
Acute kidney injury 4 (3)
Bronchopulmonary aspergillosis 3 (2)
Acute respiratory distress syndrome 3 (2)
Pulmonary embolism 3 (2)
Acute liver injuryb 3 (2)
Multiorgan failure 3 (2)
Encephalopathy 2 (2)
Ventricular arrhythmia 2 (2)
Hypoxia 2 (2)
Bacteremiac 2 (2)
a Events were graded according to DAIDS toxicity criteria; all events recorded
occurred after initiation of intravenous zanamivir treatment. Similar reported
events were grouped together by organ system and mechanism. The following
serious adverse events were reported by 1 patient: rash, thrombophlebitis or
venous thrombosis, endocarditis, viral pericarditis, chronic obstructive pulmonary
disease, hemothorax, pneumothorax, hemoptysis or pulmonary hemorrhage,
atrioventricular block complete, hemorrhage, peripheral ischemia, shock hem-
orrhagic, ischemic stroke, hyponatremia, acute leukemia, and depression.
b Acute liver injury comprised all events of cytolytic hepatitis and increased
alanine aminotransferase, hepatic enzyme, and transaminase levels.
c Including 1 case of Acinetobacter bacteremia; the organism in the second
bacteremia case was not documented.




Grade 3 or 4 adverse event 57 (44)
Bacterial pulmonary infections (including
pneumonia and bronchopneumonia)
13 (10)
Acute liver injuryb 11 (8)
Respiratory failure 8 (6)
Hypotension 8 (6)
Cardiogenic shock 6 (5)
Sepsis or septic shock 6 (5)
Neuropathy or neuromuscular disorder 6 (5)
Acute kidney injury 5 (4)
Acute respiratory distress syndrome 4 (3)
Hypertension 4 (3)
Anemia 3 (2)
Thrombophlebitis or venous thrombosis 3 (2)
Bronchopulmonary aspergillosis 3 (2)
Pleural effusion 3 (2)
Pulmonary embolism 3 (2)
Multiorgan failure 3 (2)









Ventricular arrhythmia 2 (2)
Hypoxia 2 (2)
Bacteremiac 2 (2)
a Graded according to DAIDS toxicity criteria. All events recorded occurred
after initiation of intravenous zanamivir treatment. Similar reported events
were grouped together by organ system and mechanism. The following grade
3 or 4 adverse events were each reported by 1 patient: hemolytic anemia,
bronchospasm, chronic obstructive pulmonary disease, hemothorax, lung
disorder, hemoptysis or pulmonary hemorrhage, pulmonary edema, Clostridium
difficile colitis, sinusitis, endocardisis, viral pericarditis, hemorrhage, peripheral
ischemia, shock hemorrhagic, arrhythmia, cardiac failure congestive, left ventric-
ular dysfunction, increased levels of aspartate aminotransferase, blood creatine
phosphokinase, or blood creatine, electrocardiographic QT prolongation, ischemic
stroke, agranulocytosis, lymphopenia, thrombocytopenia, hypokalemia, hypona-
tremia, hyperbilirubinemia, rhabdomyolysis, anxiety, depression, adrenal insuffi-
ciency, erosive gastritis, acute leukemia, and coagulopathy.
b Acute liver injury comprised all events of cytolytic hepatitis and increased
levels of alanine aminotransferase, hepatic enzyme, and transaminases.
c Including 1 case of Acinetobacter bacteremia; the organism in the second
bacteremia case was not documented.
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Seventeen patients (13%) experienced protocol-defined liver
AEs (n = 14; 11%) or SAEs (n = 3; 2%). The median time from
initiation of intravenous zanamivir to onset of liver AEs was 9
days (range, 1–27 days), and the median time from the last
dose of intravenous zanamivir to the onset of liver AEs was 1
day (range, 1–22 days). Except for 1 patient who died of an un-
related cause on day 3, all liver SAEs and AEs resolved or im-
proved by the end of follow-up (about 3 weeks after the last
dose of intravenous zanamivir). Eleven AEs and 2 SAEs were
considered by the investigator to be potentially attributable to
intravenous zanamivir. Of the 3 patients with liver SAEs (ALT
≥3 × ULN and total bilirubin ≥2 × ULN), 1 experienced an
SAE that resolved by the end of the study, 1 died of cardiogenic
shock (unrelated to intravenous zanamivir), and 1 (with con-
founding hepatitis C and a liver event not attributable to study
drug) died of hemothorax and multiorgan failure. Most proto-
col-defined liver events were associated with A/H1N1pdm09
infection and multiorgan failure. In the overall study popula-
tion, there were no changes in median ALT, aspartate amino-
transferase, or total bilirubin levels during or after treatment.
Twenty-six patients died, for an overall cumulative mortality
(including poststudy deaths) of 20%; 14- and 28-day cumula-
tive mortality were 13% (n = 17) and 17% (n = 22), respectively.
The most common causes of death were respiratory failure
(n = 7; 5%), sepsis or septic shock (n = 5; 4%), cardiogenic
shock (n = 4; 3%), and bacterial pulmonary infections, includ-
ing pneumonia and bronchopneumonia (n = 4; 3%). None of
the deaths was considered by the investigator to be attributable
to zanamivir treatment. No other safety signals or clinically sig-
nificant trends in laboratory values, vital signs or electrocardio-
graphic findings were identified or considered attributable to
zanamivir. All 3 pregnant patients survived and gave birth to
healthy infants. No SAEs were reported in the pregnant or
postpartum patients.
Serum Pharmacokinetics
Serum samples were obtained in 126 (97%) patients for phar-
macokinetic analysis. Results are provided in Table 4 and
Table 5. For the initial 600-mg dose on day 1 (Table 4), area
under the serum concentration–time curve extrapolated to
Table 4. Zanamivir Pharmacokinetic Parameter Estimates by Renal Function Group for Initial 600-mg Dose on Day 1a
CLcr, mL/minb
Geometric Mean (%CV) [No. of Patients]
Cmax, μg/mL AUC(0-∞) , h · µg/mL t1/2, h CL, mL/min Vss. L
≥80 32.8 (34) [67] 82.9 (36) [63] 2.39 (31) [67] 121 (36) [63] 22.0 (30) [63]
50 to <80 34.2 (19) [15] 120 (38) [15] 3.47 (73) [18] 83.4 (38) [15] 21.3 (20) [15]
30 to <50 37.7 (34) [13] 244 (27) [12] 6.11 (30) [13] 40.9 (27) [12] 20.7 (41) [12]
15 to <30 36.9 (23) [5] 729 (77) [5] 19.0 (72) [5] 13.7 (77) [5] 22.6 (23) [5]
<15 47.1 (. . .) [2] 950 (. . .) [2] 18.4 (. . .) [2] 10.5 (. . .) [2] 16.3 (. . .) [2]
Abbreviations: %CV, percent coefficient of variation; AUC(0-∞), area under the serum concentration-time curve extrapolated to infinity; CL, systemic clearance of
zanamivir; CLcr, creatinine clearance; Cmax, peak concentration at end of infusion; t½, elimination half-life; Vss, steady-state volume of distribution.
a Because of missed samples, not all pharmacokinetic parameters could be estimated for all patients.
b Denotes renal function as either CLcr or clearance estimated for continuous renal replacement therapy modality (CLCRRT), n = 4.
Table 5. Zanamivir Pharmacokinetic Parameter Estimates by Renal Function Group for Maintenance Dose on Day 3, 4, or 5a
CLcr, mL/minb
Geometric Mean (%CV) [No. of Patients]
Cmax, μg/mL Cmin, μg/mL AUC(0-τ), h · µg/mL t1/2, h CL, mL/min Vss, L
≥80 35.3 (32) [72] 0.82 (135) [76] 90.3 (36) [65] 2.56 (34) [68] 111 (36) [65] 21.6 (33) [65]
50 to <80 29.3 (27) [7] 2.19 (158) [7] 90.7 (29) [6] 3.69 (49) [6] 73.5 (29) [6] 21.4 (36) [6]
30 to <50 20.9 (30) [6] 6.10 (45) [7] 136 (24) [5] 8.50 (51) [6] 30.7 (24) [5] 22.3 (48) [5]
15 to <30 23.6 (16) [5] 16.2 (27) [5] 217 (29) [4] 36.0 (68) [4] 11.5 (29) [4] 35.6 (40) [4]
<15 7.45 (. . .) [2] 5.30 (. . .) [2] 80.1 (. . .) [2] 61.1 (. . .) [2] 12.5 (. . .) [2] 66.5 (. . .) [2]
Abbreviations: %CV, percent coefficient of variation; AUC(0-τ), area under the concentration-time curve during a 12-hour maintenance dosing interval; CL, systemic
clearance of zanamivir; CLcr, creatinine clearance; Cmax, peak concentration at end of infusion; Cmin, trough concentration during 12-hour maintenance dosing
interval; t½, elimination half-life; Vss, steady-state volume of distribution.
a Because of missed samples, not all pharmacokinetic parameters could be estimated for all patients.
b Denotes renal function as either CLcr or clearance estimated for continuous renal replacement therapy modality (CLCRRT, n = 4).
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infinity (AUC(0-∞)) values typically increased with decreasing
CLcr, from 82.9 h · µg/mL for patients with CLcr ≥80 mL/min
to 950 h · µg/mL for patients with CLcr <15 mL/min No differ-
ences were observed in maximum plasma concentration (Cmax)
between the renal function groups (range of group means,
32.8–47.1 µg/mL). During maintenance dosing, as expected,
the maximum plasma concentration decreased and the trough
plasma concentration (Cmin) increased with reduced doses for
renal impairment, but similar AUCs were observed (Table 5).
Virology
In 93 of 124 patients (75%) with influenza qRT-PCR–positive
nasopharyngeal samples at baseline, the median viral load was
5.34 log10 copies/mL, which decreased at day 3 (2 days of treat-
ment) by 1.42 log10 copies/mL (Figure 1). The median time to
no detectable virus RNA by qRT-PCR was 3 days (range, 1–31;
interquartile range, 1–5). Only 54 of 126 patients (43%) had
positive qVC results from nasopharyngeal samples at baseline;
thus, the median qVC result was below the LLQ. We found that
qVC results in this study were less reliable than qRT-PCR
results and were not used for analyses. We identified no base-
line or emergent H275Y, I223R/V/K, or Q136K mutations. De-
tailed genotypic, phenotypic, and minority species analyses will
be reported in a separate publication.
Twenty-two of 23 patients had an endotracheal sample posi-
tive for influenza by qRT-PCR (influenza A/H1N1pdm09 in
19, A/no subtype in 2, and A/H3N2 in 1). The median viral
load was 4.68 log10 copies/mL. A total of 21 patients had paired
qRT-PCR data in both endotracheal and nasopharyngeal
samples, with median viral loads of 4.89 and 3.60 log10 copies/
mL, respectively (P = .004); of these, 17 (81%) had higher viral
loads in endotracheal samples (Supplementary Figure 1; Sup-
plementary Appendix).
Clinical End Points
The median duration of hospitalization was 15 days (range 1–
133 days). One hundred eight patients (83%) had an ICU stay
during the study; the median duration was 11.5 days (range, 1–
104 days). The median time to return to predefined normal cri-
teria for each vital sign was between 2 and 8 days, but data were
highly variable (Table 6).
Sixty-four patients (49%) received systemic corticosteroids
while receiving treatment with intravenous zanamivir. The
median time to a qRT-PCR result <500 copies/mL was 3 days
among patients who received corticosteroids (range, 1–31
days), compared with 2 days among those who did not (range,
1–27 days). The cumulative mortality rate was 22% (14 of 64
patients) among patients who received corticosteroids com-
pared with 18% (12 of 66) among those who did not. The
overall rate of infection-related SAEs was lower in the cortico-
steroid group (11% vs 18%), but 3 fatal cases of pulmonary
aspergillosis occurred, all among patients who received
corticosteroids.
Exploratory Analyses
The effect of antiviral treatment on mortality rates was explored
using Cox modeling. Time-dependent exposure to intravenous
zanamivir was associated with an adjusted hazard ratio (aHR)
of 0.793 (95% confidence interval [CI], .230–2.736), accounting
for prior or subsequent oseltamivir exposure (aHR, 0.731; 95%
CI, .092–5.827) and other potential risk factors for increased
mortality rates (Table 7). The univariate analysis showed that
both H3N2 subtype and age were significantly associated with
mortality rates, but corticosteroid use was not (hazard ratio,
1.17; 95% CI, .54–2.53). There was no correlation between
Figure 1. Median change from baseline influenza A or B viral load by
quantitative real-time polymerase chain reaction in patients with positive
baseline results; interquartile ranges are also shown.
Table 6. Time Until Return to Normal Vital Signs After Initiation

















≤37.8°C 120 3 (2–34)
Oxygen
saturation
≥95% 87 8 (2–36)
Respiratory
rate
Respiration rate ≤24/min or
normal respiratory statusb
89 8 (2–36)




≥90 mm/Hg 128 2 (2–3)
a Data were censored for patients who never reached normal criteria.
b Normal respiratory status was defined as (1) a return to premorbid oxygen
requirement (2) a return to no need for supplemental oxygen, or (3) respiration
rate ≤24/min without supplemental oxygen.
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higher zanamivir exposure and drug-related AEs or protocol-
defined liver events. A weak but significant correlation (Pearson
R = 0.28; P = .003) was noted between AUC(0-∞) and the occur-
rence of SAEs, but this was confounded by the presence of
renal dysfunction at baseline. We found a weak correlation
between AUC(0-∞) and decrease of nasopharyngeal qRT-PCR
on day 3 of treatment (Pearson R = –0.23; P = .02).
We explored whether there was a relationship between base-
line levels of influenza RNA by qRT-PCR and mortality rate by
grouping patients with positive baseline qRT-PCR results (93
patients) in qRT-PCR tertiles and comparing them with those
who had negative qRT-PCR resutls at baseline (31 patients; 6
had missing values at baseline). Patients in the 2 highest tertiles
of influenza qRT-PCR had cumulative mortality rates of 23%
and 22%, respectively; patients in the lower tertile (<4.57 log10
copies/mL) had a cumulative mortality rate of 17%, and this
rate among patients with negative baseline qRT-PCR results
was 13%. We also explored whether the change in nasopharyn-
geal influenza viral load from baseline to day 3 (n = 82 with
paired samples) was associated with mortality rates. We found
no association between change in viral load from baseline and
mortality rate by Cox modeling (P = .92); deaths were evenly
distributed between those who experienced changes from base-
line greater than −1.42 log10 by treatment day 3 (8 subjects)
and those who experienced smaller changes (7 subjects).
DISCUSSION
In this open-label, international, phase 2 trial we prospectively
assessed the safety, tolerability, virologic effects, and pharmaco-
kinetics of intravenous zanamivir (600 mg every 12 hours, ad-
justed for renal dysfunction) in 130 hospitalized adults with
confirmed influenza, most of whom had associated pneumonia
and were treated in an ICU. The all-cause cumulative mortality
rate in this trial was 20%, and the 28-day mortality rate was
17%. Both intravenous zanamivir and oseltamivir use were as-
sociated with lower aHR for death when modeled as time-
dependent exposures. The observed mortality rate was lower
but consistent with retrospective cohort studies of critically ill
hospitalized patients with influenza during this time period
[20–25]. For example, in critically ill patients with 2009 influen-
za A/H1N1pdm09, a 50% ICU mortality rate has been reported
[25], and a California-cohort study in 1950 patients reported a
25% mortality rate with neuraminidase treatment (median time
from symptom onset, 4 days) and a 42% mortality rate without
treatment [26]. Of the 26 deaths in this study, none was thought
by the treating physician to be attributable to zanamivir. The
small number of pregnant women did well clinically, with no
observed adverse fetal effects.
Influenza viral load analyses suggested that intravenous za-
namivir had a rapid antiviral effect, with a median decrease in
viral load of 1.42 log10 copies/mL after 2 days of treatment,
despite the presence of symptoms for a median of 4.5 days
before study entry and prior use of oseltamivir in 80% of pa-
tients. This viral load reduction is consistent with findings of
previous studies of inhaled zanamivir in acute uncomplicated
seasonal influenza and limited data from hospitalized patients
during the pandemic [27, 28]. In a Hong Kong study of 66
adults with influenza A/H1N1pdm09, patients with severe
pneumonia experienced a longer duration of viral RNA positiv-
ity (by nasopharyngeal swab sample) after starting oseltamivir
treatment (median, 6 days; range, 3–8) than those with milder
illness (median, 2 days; range, 1–3) [29]. In our study, higher
virus loads were observed in endotracheal samples than in
Table 7. Covariate Effects on Mortality Rates by Cox Modelinga
Covariates
Univariate Model Multivariate model
HR 95% CI Adjusted HR 95% CI
Zanamivir on vs off 0.651 .202–2.102 0.793 .230–2.736
Oseltamivir on vs off 0.754 .096–5.933 0.731 .092–5.827
Female vs male sex 0.942 .428–2.073 1.153 .513–2.590
H3N2 vs other 4.202 1.793–9.848 2.460 .853–7.098
Baseline mechanical ventilation vs none 0.882 .406–1.918 0.951 .417–2.171
Immunomodulator vs noneb 0.566 .076–4.194 0.488 .063–3.792
Age in years 1.039 1.012–1.067 1.017 .982–1.052
Body mass index, kg/m2 0.962 .909–1.018 0.985 .928–1.046
Baseline creatinine clearance, mL/min 0.991 .984–.998 0.995 .986–1.004
Baseline viral load, log10 copies/mL 1.096 .878–1.369 0.949 .741–1.216
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Survival time starts from symptom onset date. Zanamivir and oseltamivir were modeled as daily time-dependent covariates.
b Immunomodulators (used during treatment with intravenous zanamivir) included cyclosporin, tacrolimus, azathioprine, capecitabine, cisplatin hydroxycarbamide,
mycophenolate mofetil, mycophenolate sodium, mycophenolic acid, nilotinib, and sirolimus.
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simultaneous nasopharyngeal samples, reflecting the lower re-
spiratory tract burden of influenza illness in this patient popu-
lation [30]. In this study, we found a poor correlaton between
the qVC and qRT-PCR results. The reason is not clear, but the
qRT-PCR data were considered more reliable and have been
presented to describe antiviral efficacy.
In most cases, the causal connection between AEs and zana-
mivir was confounded by influenza severity, underlying medical
conditions, and numerous concomitant medications, including
antibiotics in 92% (data not shown). Protocol-defined liver
events were observed in 13% of the study population; in all pa-
tients except 1 who died imminently of cardiogenic shock, liver
enzyme elevations resolved with resolution of influenza or criti-
cal illness. Intravenous zanamivir was not noted to increase liver
chemistry values in phase I healthy volunteer studies or preclini-
cal animal safety studies [31, 32]. In our study, liver events did
not correlate with higher zanamivir exposure, and there were no
overall increases or discernible pattern in liver enzyme results,
with many patients experiencing liver enzyme elevations at base-
line, during treatment, or after treatment. Liver enzyme elevation
has also been described in critically ill patients with influenza A/
H1N1pdm09 [33]. It is unclear whether intravenous zanamivir
had a role in causing or exacerbating underlying liver inflamma-
tion. To address this uncertainty further, a current phase 3 trial
of intravenous zanamivir in hospitalized adults with influenza is
testing 2 dose levels of intravenous zanamivir (600 or 300 mg
twice daily) and comparing them with oral oseltamivir (clinical-
trials.gov, NCT01231620).
Zanamivir pharmacokinetic parameters in this severely ill
population were generally consistent with results of previous
studies in healthy volunteers [34], although variability was
greater. Dose adjustments for patients with renal impairment
resulted in AUCs similar to those in patients with normal renal
function. Pharmacokinetic parameters for patients receiving
continuous renal replacement therapy or extracorporeal mem-
brane oxygenation seemed similar to those for patients not un-
dergoing these procedures (data not shown). However, few
patients underwent continuous renal replacement therapy
(n = 14) or extracorporeal membrane oxygenation (n = 4), and
only 4 had simultaneous pharmacokinetic parameters. Thus,
additional data are required to confirm these findings.
This study was limited by its single-arm, uncontrolled, open-
label design and the critically ill nature of the patient population.
Although a potential clinical benefit is difficult to assess without
a control group, the safety and clinical outcomes observed in this
study are consistent with those expected in patients with severe
influenza and reflect a real-life clinical setting.
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